Lexeo Therapeutics, Inc. Logo

Lexeo Therapeutics, Inc.

Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.

LXEO | US

Overview

Corporate Details

ISIN(s):
US52886X1072
LEI:
Country:
United States of America
Address:
345 PARK AVENUE SOUTH, 10010 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing curative treatments for genetically defined diseases. The company advances a pipeline of investigational AAV-mediated gene therapies, with a primary focus on genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease. Building on foundational research from Weill Cornell Medicine and the University of California San Diego, Lexeo's strategy prioritizes efficient development, advanced manufacturing, and strategic partnerships with leading research institutions to develop high-impact therapeutic candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lexeo Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lexeo Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lexeo Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sugentech, Inc. Logo
Develops advanced in-vitro diagnostic systems for hospitals, clinics, and at-home use.
South Korea
253840
SUHEUNG CO.,LTD. Logo
Global manufacturer of capsules and contract manufacturing for pharma/nutraceutical industries.
South Korea
008490
Sumitomo Pharma Co., Ltd. Logo
R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.
Japan
4506
Summit Therapeutics Inc. Logo
Advancing a Phase 3 bispecific antibody for lung cancer and other solid tumors.
United States of America
SMMT
SunBio, Inc. Logo
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea
067370
Sunshine Biopharma Inc. Logo
Develops novel oncology/antiviral drugs and commercializes generic pharmaceuticals in Canada.
United States of America
SBFM
SUPERNUS PHARMACEUTICALS, INC. Logo
Develops and commercializes therapies for CNS diseases like epilepsy, migraine, and ADHD.
United States of America
SUPN
SUTRO BIOPHARMA, INC. Logo
Develops engineered cancer drugs like ADCs using a cell-free protein synthesis platform.
United States of America
STRO
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden
SOBI
SymBio Pharmaceuticals Limited Logo
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan
4582

Talk to a Data Expert

Have a question? We'll get back to you promptly.